Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$14.31M-91.21%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dennis Lanfear
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 144
- Beta
- 0.95
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.73
Financials
Revenue
$14.31M-91.2%Net Income
$-20.63M-124.6%EBITDA
$-30.16M-134.7%Free Cash Flow
$-119.98MEPS (diluted)
$-0.13-107.8%Shares Outstanding (diluted)
154.82M+200.1%Operating Expenses
$42.40MCash & Debt
$105.31MReturn of Capital
$0.00Revenue by Segment (annual)
$1.34MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.17M | $-170.29M | $-1.45 |
| 2024 | $266.96M | $28.51M | $0.25 |
| 2023 | $257.24M | $-237.89M | $-2.53 |
| 2022 | $211.04M | $-291.75M | $-3.76 |
| 2021 | $326.55M | $-287.10M | $-3.81 |
| 2020 | $475.82M | $132.24M | $1.85 |
| 2019 | $356.07M | $89.83M | $1.29 |
| 2018 | $1.56M | $-209.34M | $-3.22 |
| 2017 | $1.56M | $-238.17M | $-4.48 |
| 2016 | $190.11M | $-127.34M | $-3.04 |
| 2015 | $30.04M | $-223.26M | $-6.01 |
| 2014 | $31.11M | $-87.13M | $-10.64 |
| 2013 | $2.75M | $-53.63M | $-2.97 |
| 2012 | $1.90M | $-33.02M | $-11.69 |
Valuation
CHRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·19d ago·Positive
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·36d ago·Negative
Coherus to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·49d ago·Negative
…oherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.21 per share
Typical surprise -3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.19 vs $-0.25beat
- Mon, May 11$-0.25 vs $-0.26beat
- Mon, Mar 9$-0.34 vs $-0.36beat
- Thu, Nov 6$-0.33 vs $-0.32miss
- Thu, Aug 7$-0.34 vs $-0.31miss
- Mon, May 12$-0.35 vs $-0.31miss
Estimates and results for CHRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CHRS officers and directors.
- Bought
- —
- Sold
- $524k
0 trades
2 trades
- Wahlstrom Matssold
- Lanfear Dennis Msold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CHRS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.